about
Fat grafting for breast cancer patients: From basic science to clinical studies.GD2 expression in breast cancer.Rare breast cancer subtypes: histological, molecular, and clinical peculiaritiesPrognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerMutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter studyClinical development of mTOR inhibitors in breast cancer.Timing for starting second-line therapy in recurrent ovarian cancer.Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.Relapsed triple-negative breast cancer: challenges and treatment strategies.Quantification of residual risk of relapse in breast cancer patients optimally treated.New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.The immune system and hormone-receptor positive breast cancer: Is it really a dead end?Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract CaLandscape and evolution of therapeutic research for breast cancer patients.First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience.Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome.Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.Whole exome sequencing of rare aggressive breast cancer histologies.Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in IImmune characterization of breast cancer metastases: prognostic implications.Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group oOlaparib for the treatment of breast cancerEscalation and de-escalation in HER2 positive early breast cancerGender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM)
P50
Q30249805-8DBF2FBB-EF8B-49B3-A4F2-7B2885BC5777Q33761830-81D73F06-DB7F-40CC-B251-9B7CC7DCE783Q34005143-3CF14E40-46FA-4B8C-B59B-C92C13B0B19AQ35879081-68AD99B9-304E-491B-AE3B-AC0A0F0253E6Q36064908-FC2F6963-B8CB-4820-B46C-86A6E37EBE9DQ36233937-31D2FE8F-7289-4456-A381-3CBF8D1E398EQ37600494-07DF3E8C-0201-4779-B5CD-8D6647F45C37Q37690076-2311ABCB-DA7A-4D51-A86A-EB415F03FB4FQ37821896-8AEFA484-47EB-45D2-B7AD-D1C3C5658A8FQ37977498-E600CBF0-1015-4265-99FE-260F201C0039Q38069133-8014D657-BFC8-4373-B883-D1D400B70DDAQ38082503-9CEE5FDC-560F-4C66-A575-33C4B456E36FQ38120666-6662DD04-617B-4378-BBD5-B582CE920EE6Q38145856-5F6458D4-5715-4C42-BF3E-2FF0DCC21A9BQ38149797-FAA473D2-8CE3-4CAF-84AD-94F6D14E47A4Q38222277-FBFD2C1F-B09D-48A6-B1F7-91D7D18FF4E1Q38719132-3C6185CE-49A8-4FE3-8F96-A82AF77C5E9FQ38800892-24B8B286-B034-420E-B0A3-F5CF280CD1F3Q42328025-47F9BA73-1CE6-465E-A497-9C9061CAF280Q42497114-7AA928B0-F515-4121-A5E4-705D1E8C861BQ44723581-1DF32849-FB97-4E7E-BF07-6FCF5CC295DBQ46466675-3E0153FC-83BC-440C-B984-431348456C19Q46540302-3D602093-4A17-4081-AB9D-0282F562A596Q46837888-47997AB5-6DC7-4C0F-8946-8F7EAA58CE09Q47604446-2A1EC074-74B0-47F0-807C-264730884D75Q47676268-41067B12-1553-48A1-A686-CC4843F60870Q47712466-5C6DE3F3-BC99-469A-93A7-E0DB74A8FE24Q48220922-BC6F11DF-0F0C-4E13-B046-D010CDEFEEDDQ50862543-701E5094-7411-49A1-A46D-0CC85A43FB48Q51663342-06A9F846-D812-4E59-96DA-27F360A5B0A3Q51835410-C5D3D6E7-066C-41FC-A19A-74BDDB9DE1A1Q53080309-827AD8B2-49B9-4DFA-B2C8-9FEC2A978763Q53166630-F285C394-15EA-489F-A9EF-3B2AAA25D9FAQ53445409-0B18CE04-83EF-451A-B64B-5257FF3DE9A9Q54685474-39F41D9A-0C15-4247-BFC5-4CE0B936EFA7Q55450758-AB38AF29-C403-4208-880A-9235E7C13CF2Q57105469-753AC5C6-0CF2-4268-843D-06A98F2FB96FQ57112150-0595C65D-542E-43AE-8B97-643CFB671C40Q57470753-D1597908-9828-4796-A501-1206C178B796Q58694191-AD2E7F9F-61C9-44F7-A5E5-F60F0C46FDF5
P50
description
researcher ORCID ID = 0000-0002-3967-9861
@en
wetenschapper
@nl
name
Maria Vittoria Dieci
@ast
Maria Vittoria Dieci
@en
Maria Vittoria Dieci
@es
Maria Vittoria Dieci
@nl
type
label
Maria Vittoria Dieci
@ast
Maria Vittoria Dieci
@en
Maria Vittoria Dieci
@es
Maria Vittoria Dieci
@nl
prefLabel
Maria Vittoria Dieci
@ast
Maria Vittoria Dieci
@en
Maria Vittoria Dieci
@es
Maria Vittoria Dieci
@nl
P108
P106
P1153
24821668600
P21
P31
P496
0000-0002-3967-9861